APA (7th ed.) Citation

Strati, P., Ahmed, M. A., Nastoupil, L. J., Feng, L., Hagemeister, F. B., Fayad, L. E., . . . Fowler, N. H. (2020). Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. Leukemia & Lymphoma, 61(6), 1380. https://doi.org/10.1080/10428194.2020.1716221

Chicago Style (17th ed.) Citation

Strati, Paolo, et al. "Pretreatment SUVmax May Influence the Clinical Benefit of BR over R-CHOP in Patients with Previously Untreated FL." Leukemia & Lymphoma 61, no. 6 (2020): 1380. https://doi.org/10.1080/10428194.2020.1716221.

MLA (9th ed.) Citation

Strati, Paolo, et al. "Pretreatment SUVmax May Influence the Clinical Benefit of BR over R-CHOP in Patients with Previously Untreated FL." Leukemia & Lymphoma, vol. 61, no. 6, 2020, p. 1380, https://doi.org/10.1080/10428194.2020.1716221.